You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
150 Items
Cancer Type: Lung     
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
DOXOrubicin,
CISplatin,
vinCRIStine,
cyclophosphamide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Genitourinary, Testis     
Intent: Adjuvant, Curative
Drugs Used:
bleomycin,
etoposide,
CISplatin
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Genitourinary, Testis     
Intent: Adjuvant, Curative
Drugs Used:
bleomycin,
etoposide,
CISplatin
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Gynecologic, Germ Cell     
Intent: Adjuvant
Drugs Used:
bleomycin,
CISplatin,
etoposide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Gynecologic, Germ Cell     
Intent: Curative
Drugs Used:
PACLitaxel,
bleomycin,
etoposide,
CISplatin
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Genitourinary, Testis     
Intent: Curative
Drugs Used:
PACLitaxel,
bleomycin,
CISplatin,
etoposide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
... Show more tags
Drugs Used:
bortezomib,
daratumumab,
dexamethasone
... Show more tags
Quick Link(s):
Regimen Monograph
Sep 2019
Cancer Type: Hematologic, Myeloproliferative Neoplasms (MPNs)     
Intent: Palliative
Funding:
ODB - General Benefit
    busulfan - oral tablets
... Show more tags
Drugs Used:
busulfan
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Lung, Thymoma     
Intent: Palliative
Drugs Used:
cyclophosphamide,
DOXOrubicin,
CISplatin
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2017
Cancer Type: Head and Neck     
Intent: Palliative
Drugs Used:
cyclophosphamide,
DOXOrubicin,
CISplatin
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
... Show more tags
Drugs Used:
CISplatin,
capecitabine
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
... Show more tags
Drugs Used:
CISplatin,
capecitabine
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019